Venous thromboembolism in pregnancy and the puerperium

A 33-year-old woman at 34 weeks gestation, BMI 38, presents to the maternity assessment unit with a one-day history of left calf swelling and pleuritic chest pain. She had an emergency caesarean in her first pregnancy and a maternal aunt with a pulmonary embolism. Her oxygen saturation is 96 per cent on room air. This is VTE until proven otherwise, and the next two hours will decide whether the diagnosis is made safely. The decisions — diagnostic pathway, anticoagulation dose, the planned delivery and the postpartum duration — are the decisions this topic rehearses.^[1][3]

Overview and definition

Venous thromboembolism in pregnancy encompasses deep vein thrombosis (DVT) and pulmonary embolism (PE) occurring during pregnancy or within six weeks of delivery. It is one of the leading direct causes of maternal mortality in high-income settings, and it is largely preventable with appropriate risk assessment and prophylaxis.^[1][3]

Three principles frame the topic:^[1]

• Pregnancy is a hypercoagulable state. VTE risk is four to five times that of non-pregnant women of the same age, and the postpartum period carries the highest risk.^[3]
• Diagnosis is harder in pregnancy. Symptoms overlap with physiological pregnancy complaints, d-dimer is raised throughout pregnancy, and the choice of imaging must weigh maternal and fetal radiation dose.^[4][9]
• Treatment is heparin, not warfarin. Low-molecular-weight heparin is the agent of choice for both treatment and prophylaxis; warfarin is teratogenic in weeks 6 to 12 and causes fetal intracranial haemorrhage in the third trimester.^[1][2]

Two numbers anchor the topic. The prevalence of pregnancy-related VTE is roughly 1 to 2 per 1000 pregnancies, and the postpartum period accounts for a disproportionate share of fatal events.^[3][16]

References16ShowHide

1. [1]Bates SM, Rajasekhar A, Middeldorp S, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy Blood Adv, 2018.PMID 30482767
2. [2]Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest, 2012.PMID 22315276
3. [3]American College of Obstetricians and Gynecologists' Committee on Practice Bulletins-Obstetrics ACOG Practice Bulletin No. 196: Thromboembolism in Pregnancy Obstet Gynecol, 2018.PMID 29939938
4. [4]Leung AN, Bull TM, Jaeschke R, et al. An official American Thoracic Society/Society of Thoracic Radiology clinical practice guideline: evaluation of suspected pulmonary embolism in pregnancy Am J Respir Crit Care Med, 2011.PMID 22086989
5. [5]Scarsbrook AF, Bradley KM, Gleeson FV Perfusion scintigraphy: diagnostic utility in pregnant women with suspected pulmonary embolic disease Eur Radiol, 2007.PMID 17342484
6. [6]Greer IA Low-molecular-weight heparin for pregnancy complications Lancet, 2016.PMID 27720498
7. [7]Greer IA Thrombosis in pregnancy: updates in diagnosis and management Hematology Am Soc Hematol Educ Program, 2012.PMID 23233582
8. [8]Lamont MC, McDermott C, Thomson AJ United Kingdom recommendations for obstetric venous thromboembolism prophylaxis: Evidence and rationale Semin Perinatol, 2019.PMID 30935752
9. [9]Chan WS Diagnosis of venous thromboembolism in pregnancy Thromb Res, 2018.PMID 28935434
10. [10]Chan WS Can pregnancy-adapted algorithms avoid diagnostic imaging for pulmonary embolism? Hematology Am Soc Hematol Educ Program, 2020.PMID 33275675
11. [11]Bistervels IM, Buchmüller A, Wiegers HMG, et al. Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial Lancet, 2022.PMID 36354038
12. [12]Rodger MA, Phillips P, Kahn SR, et al. Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial Thromb Haemost, 2015.PMID 25373438
13. [13]Duhl AJ Low-molecular-weight heparins for the prevention and treatment of venous thromboembolism in at-risk pregnant women J Reprod Med, 2008.PMID 18839817
14. [14]Pandor A, Daru J, Hunt BJ, et al. Risk assessment models for venous thromboembolism in pregnancy and in the puerperium: a systematic review BMJ Open, 2022.PMID 36223963
15. [15]Davis S, Pandor A, Sampson FC, et al. Thromboprophylaxis during pregnancy and the puerperium: a systematic review and economic evaluation to estimate the value of future research Health Technol Assess, 2024.PMID 38476084
16. [16]Sultan AA, West J, Grainge MJ, et al. Development and validation of risk prediction model for venous thromboembolism in postpartum women: multinational cohort study BMJ, 2016.PMID 27919934